What is ILMN(Illumina) average time for price targets to be met?

On average it took 203.03 days on average for the stock forecasts to be realized with a an average price target met ratio 75.77.

ILMN - Illumina Stock - Displayed [399 Analyst Price Targets]

ILMN - Illumina - Stock Forecast

Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

ILMN is currently covered by 19 analysts with an average price target of $109.92. This is a potential upside of $32.04 (41.14%) from yesterday's end of day stock price of $77.88.

Illumina's activity chart (see below) currently has 399 price targets and 330 ratings on display. The stock rating distribution of ILMN is 39.08% BUY, 51.72% HOLD and 9.2% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 75.77% with an average time for these price targets to be met of 203.03 days.

Highest price target for ILMN is $190, Lowest price target is $77, average price target is $146.8.

Most recent stock forecast was given by LUKE SERGOTT from BARCLAYS on 10-Apr-2025.

Overview

Illumina is a life science tools and integrated systems company that focuses on large-scale analysis of genetic variation and function. The company operates through two segments, Core Illumina and GRAIl:

The Core Illumina segment develops and markets genomic analysis products and services. This segment’s products are used for applications such as cancer research, reproductive and genetic health, and agriculture.
The GRAIL segment focuses on developing multi-cancer early detection tests using Illumina’s sequencing technology. The GRAIL segment aims to develop blood tests that can detect multiple types of cancer at an early stage.

The company’s Galleri test is a multi-cancer early detection test that can detect more than 50 types of cancer through a simple blood draw.

In addition to its products, Illumina provides a range of services including whole-genome sequencing, genotyping, non-invasive prenatal testing (NIPT), and product support services.

History

Illumina was incorporated in 1998 and is headquartered in San Diego, California.

Illumina in the News

Illumina (ILMN) Earnings Expected to Grow: Should You Buy?

The market expects Illumina (ILMN) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company’s earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to...

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO, May 1, 2025 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization...